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GLOSSARY OF TERMS AND ABBREVIATIONS 
CRM-negative 
CRM-positive 
factor IX activity 
factor IX antigen 
factor IX inhibitor 
hemophilia B-
hemophilia B + 
hemophilia B Leyden 
hemophilia BM 
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plasma in which the immunologically esti-
mated level of a protein and the level of its 
biological activity are equal. 
plasma in which a significant excess is found 
of the immunologically estimated level of a 
protein over the level of its biological activ-
ity. 
clotting factor IX measured by its biological 
activity in the blood clotting mechanism. 
factor IX protein measured by an im-
munological assay, is therefore a synonym 
for factor IX-CRM i.e., material that pro-
duces a cross-reaction with antibodies against 
factor IX. 
antibody against factor IX present in the 
plasma of approximately 5% of patients with 
severe hemophilia B after treatment with 
factor IX transfusions. 
variant of hemophilia B in which the plasma 
is CRM-negative. 
variant of hemophilia B in which the plasma 
is CRM-positive. 
variant of hemophilia B in which the bleeding 
symptoms disappear after puberty along with 
a gradual increase of both factor IX activity 
and antigen level. 
variant of hemophilia B+ in which a pro-
longed ox-brain thromboplastin-time is found. 
INA 
obligatory hemophilia carrier 
PIVKA 
inhibitor neutralization assay. 
a women who is definitely a carrier of hemo-
philia on the basis of her family history i.e.: 
a daughter of a hemophiliac or a woman 
with hemophilic relatives who has at least 
one hemophilic son, or a woman who has 
two or more hemophilic sons. 
Protein Induced by Vitamen K Absence ( or 
in the presence of Vitamin K Antagonist); 
biologically inactive precursor of the vitamin 
K dependent clotting factors (II, VII, IX, X) 
that can be demonstrated by immunological 
assays. 
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